Ginell Post
Concepts (263)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 3 | 2019 | 45 | 0.970 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2024 | 110 | 0.760 |
Why?
| | Plasma Cells | 4 | 2018 | 234 | 0.750 |
Why?
| | Epidural Neoplasms | 1 | 2019 | 4 | 0.630 |
Why?
| | ABO Blood-Group System | 1 | 2019 | 16 | 0.620 |
Why?
| | Spinal Cord Compression | 1 | 2019 | 13 | 0.620 |
Why?
| | von Willebrand Factor | 1 | 2019 | 42 | 0.610 |
Why?
| | Monocytes | 1 | 2019 | 126 | 0.590 |
Why?
| | Pseudolymphoma | 1 | 2018 | 4 | 0.580 |
Why?
| | Scalp Dermatoses | 1 | 2018 | 5 | 0.580 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 83 | 0.570 |
Why?
| | Antigens, CD | 1 | 2019 | 217 | 0.570 |
Why?
| | Hematologic Neoplasms | 1 | 2019 | 101 | 0.560 |
Why?
| | Optics and Photonics | 1 | 2017 | 8 | 0.540 |
Why?
| | Blood Coagulation Tests | 1 | 2017 | 18 | 0.540 |
Why?
| | Endemic Diseases | 1 | 2017 | 26 | 0.540 |
Why?
| | Diagnostic Tests, Routine | 1 | 2017 | 31 | 0.530 |
Why?
| | Tumor Microenvironment | 1 | 2019 | 274 | 0.530 |
Why?
| | Immunoglobulins | 1 | 2017 | 76 | 0.520 |
Why?
| | Histoplasmosis | 1 | 2017 | 48 | 0.520 |
Why?
| | Interleukin-6 | 1 | 2016 | 272 | 0.450 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 6 | 0.450 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.450 |
Why?
| | Antifungal Agents | 1 | 2017 | 350 | 0.450 |
Why?
| | Leukemoid Reaction | 1 | 2014 | 6 | 0.440 |
Why?
| | Liposarcoma | 1 | 2014 | 22 | 0.430 |
Why?
| | Muscle Neoplasms | 1 | 2014 | 17 | 0.430 |
Why?
| | Receptors, Adrenergic, alpha-1 | 3 | 2003 | 13 | 0.410 |
Why?
| | Lymphoma | 3 | 2024 | 71 | 0.410 |
Why?
| | Neoplasms, Second Primary | 1 | 2014 | 75 | 0.410 |
Why?
| | Sarcoma | 1 | 2014 | 72 | 0.410 |
Why?
| | Neutrophils | 1 | 2014 | 153 | 0.400 |
Why?
| | Humans | 31 | 2025 | 53230 | 0.380 |
Why?
| | Afibrinogenemia | 1 | 2012 | 5 | 0.380 |
Why?
| | Fetomaternal Transfusion | 1 | 2012 | 2 | 0.380 |
Why?
| | Plasma Exchange | 1 | 2012 | 25 | 0.370 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2012 | 27 | 0.360 |
Why?
| | Cell Differentiation | 1 | 2015 | 681 | 0.360 |
Why?
| | Liver | 1 | 2017 | 1150 | 0.360 |
Why?
| | Graft vs Host Disease | 1 | 2011 | 93 | 0.320 |
Why?
| | Myeloproliferative Disorders | 1 | 2010 | 31 | 0.320 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2011 | 266 | 0.310 |
Why?
| | Bone Neoplasms | 1 | 2011 | 188 | 0.300 |
Why?
| | Liver Transplantation | 1 | 2011 | 174 | 0.290 |
Why?
| | Multiple Myeloma | 4 | 2019 | 3082 | 0.290 |
Why?
| | Translocation, Genetic | 1 | 2010 | 266 | 0.290 |
Why?
| | Phenotype | 2 | 2019 | 803 | 0.250 |
Why?
| | Pancytopenia | 3 | 2011 | 37 | 0.240 |
Why?
| | Male | 13 | 2025 | 27435 | 0.230 |
Why?
| | Immunohistochemistry | 3 | 2017 | 975 | 0.230 |
Why?
| | Female | 12 | 2025 | 28782 | 0.220 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2025 | 31 | 0.220 |
Why?
| | Guanine Nucleotide Exchange Factors | 2 | 2013 | 18 | 0.210 |
Why?
| | Lymph Nodes | 2 | 2016 | 252 | 0.200 |
Why?
| | Diagnosis, Differential | 3 | 2018 | 1038 | 0.200 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 208 | 0.200 |
Why?
| | Peptide Hydrolases | 2 | 2014 | 63 | 0.190 |
Why?
| | Macrophages | 2 | 2019 | 380 | 0.190 |
Why?
| | Heterotrimeric GTP-Binding Proteins | 1 | 2002 | 6 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2002 | 17 | 0.190 |
Why?
| | Immunophenotyping | 2 | 2025 | 118 | 0.190 |
Why?
| | Receptors, Immunologic | 1 | 2002 | 36 | 0.190 |
Why?
| | Myocardium | 2 | 2003 | 471 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2003 | 152 | 0.190 |
Why?
| | Rad52 DNA Repair and Recombination Protein | 1 | 2022 | 3 | 0.180 |
Why?
| | Immunoglobulin Class Switching | 1 | 2022 | 8 | 0.180 |
Why?
| | Immunoglobulin D | 1 | 2022 | 4 | 0.180 |
Why?
| | Enzyme Activators | 1 | 2002 | 8 | 0.180 |
Why?
| | Biopsy | 2 | 2016 | 600 | 0.180 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2002 | 21 | 0.180 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 71 | 0.180 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 175 | 0.180 |
Why?
| | Escherichia coli Proteins | 1 | 2002 | 54 | 0.180 |
Why?
| | Middle Aged | 5 | 2019 | 13419 | 0.170 |
Why?
| | Bone Marrow | 2 | 2025 | 359 | 0.170 |
Why?
| | Bacterial Proteins | 2 | 2014 | 347 | 0.160 |
Why?
| | Tissue Array Analysis | 1 | 2019 | 45 | 0.160 |
Why?
| | Paraffin Embedding | 1 | 2019 | 52 | 0.150 |
Why?
| | Sarcoma, Myeloid | 1 | 2019 | 20 | 0.150 |
Why?
| | Glycosylation | 1 | 2019 | 104 | 0.150 |
Why?
| | Adolescent | 3 | 2019 | 6907 | 0.150 |
Why?
| | Aged, 80 and over | 2 | 2018 | 3494 | 0.150 |
Why?
| | Lung Neoplasms | 2 | 2024 | 645 | 0.150 |
Why?
| | Mice | 9 | 2024 | 5982 | 0.140 |
Why?
| | Color | 1 | 2018 | 17 | 0.140 |
Why?
| | Automation | 1 | 2018 | 19 | 0.140 |
Why?
| | Lymphatic Vessels | 1 | 2018 | 45 | 0.140 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 147 | 0.140 |
Why?
| | Prothrombin Time | 1 | 2017 | 18 | 0.140 |
Why?
| | Partial Thromboplastin Time | 1 | 2017 | 15 | 0.140 |
Why?
| | Failure to Thrive | 1 | 2017 | 19 | 0.140 |
Why?
| | Histoplasma | 1 | 2017 | 24 | 0.130 |
Why?
| | Clonal Evolution | 1 | 2018 | 59 | 0.130 |
Why?
| | Rare Diseases | 1 | 2017 | 47 | 0.130 |
Why?
| | Endothelial Cells | 1 | 2019 | 289 | 0.130 |
Why?
| | Blood Coagulation | 1 | 2017 | 65 | 0.130 |
Why?
| | Gene Expression Regulation | 1 | 2002 | 1003 | 0.130 |
Why?
| | Vomiting | 1 | 2017 | 71 | 0.130 |
Why?
| | Biopsy, Needle | 1 | 2017 | 181 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 180 | 0.120 |
Why?
| | Animals | 11 | 2024 | 13526 | 0.120 |
Why?
| | Flow Cytometry | 1 | 2018 | 400 | 0.120 |
Why?
| | Young Adult | 2 | 2019 | 4511 | 0.120 |
Why?
| | Neoplasm, Residual | 1 | 2017 | 171 | 0.120 |
Why?
| | Risk Assessment | 2 | 2017 | 1368 | 0.120 |
Why?
| | Lung | 1 | 2019 | 481 | 0.120 |
Why?
| | Algorithms | 1 | 2019 | 667 | 0.120 |
Why?
| | Weight Loss | 1 | 2017 | 257 | 0.120 |
Why?
| | Infant | 3 | 2025 | 3805 | 0.110 |
Why?
| | V(D)J Recombination | 1 | 2015 | 4 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2013 | 1569 | 0.110 |
Why?
| | Pyridines | 2 | 2008 | 135 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2014 | 193 | 0.100 |
Why?
| | Neoplasm Metastasis | 2 | 2012 | 237 | 0.100 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 452 | 0.100 |
Why?
| | Protein Kinases | 1 | 2014 | 72 | 0.100 |
Why?
| | Aged | 3 | 2019 | 10429 | 0.100 |
Why?
| | Transcription Factors | 2 | 2014 | 571 | 0.100 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 83 | 0.100 |
Why?
| | Rh Isoimmunization | 1 | 2012 | 2 | 0.090 |
Why?
| | Rho(D) Immune Globulin | 1 | 2012 | 3 | 0.090 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2012 | 15 | 0.090 |
Why?
| | Synaptophysin | 1 | 2012 | 7 | 0.090 |
Why?
| | Chromogranins | 1 | 2012 | 6 | 0.090 |
Why?
| | Vimentin | 1 | 2012 | 31 | 0.090 |
Why?
| | Follow-Up Studies | 1 | 2017 | 2318 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 134 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1232 | 0.090 |
Why?
| | Virulence Factors | 1 | 2012 | 79 | 0.090 |
Why?
| | Leukemia, Myelomonocytic, Chronic | 1 | 2011 | 21 | 0.090 |
Why?
| | Leukocytosis | 1 | 2011 | 11 | 0.090 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2012 | 177 | 0.090 |
Why?
| | Chimerism | 1 | 2011 | 7 | 0.090 |
Why?
| | Blotting, Western | 2 | 2002 | 587 | 0.080 |
Why?
| | Plateletpheresis | 1 | 2010 | 7 | 0.080 |
Why?
| | Telomerase | 1 | 2010 | 26 | 0.080 |
Why?
| | Blood Preservation | 1 | 2010 | 27 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2011 | 87 | 0.080 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2010 | 15 | 0.080 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2010 | 18 | 0.080 |
Why?
| | Adult | 3 | 2019 | 14534 | 0.080 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2010 | 20 | 0.080 |
Why?
| | Keratinocytes | 1 | 2011 | 91 | 0.080 |
Why?
| | Blood Proteins | 1 | 2010 | 84 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2019 | 6819 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2011 | 188 | 0.080 |
Why?
| | Anaphylaxis | 1 | 2010 | 69 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2011 | 145 | 0.080 |
Why?
| | Staphylococcus aureus | 1 | 2012 | 313 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2013 | 561 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2017 | 5595 | 0.070 |
Why?
| | Neural Tube Defects | 1 | 2008 | 33 | 0.070 |
Why?
| | Thoracic Wall | 1 | 2008 | 8 | 0.070 |
Why?
| | Copper | 1 | 2008 | 47 | 0.070 |
Why?
| | Benzenesulfonates | 1 | 2008 | 10 | 0.070 |
Why?
| | Blood Platelets | 1 | 2010 | 247 | 0.070 |
Why?
| | Neurilemmoma | 1 | 2008 | 25 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2008 | 25 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2010 | 224 | 0.070 |
Why?
| | Skin | 1 | 2011 | 419 | 0.070 |
Why?
| | Rats | 3 | 2003 | 3162 | 0.070 |
Why?
| | Mice, Knockout | 3 | 2022 | 910 | 0.060 |
Why?
| | Inflammation | 1 | 2010 | 652 | 0.060 |
Why?
| | Phagocytosis | 1 | 2025 | 59 | 0.060 |
Why?
| | Isoenzymes | 2 | 2003 | 165 | 0.060 |
Why?
| | Pregnancy | 1 | 2012 | 2608 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2012 | 2913 | 0.050 |
Why?
| | Animals, Newborn | 2 | 2003 | 357 | 0.050 |
Why?
| | Heart | 2 | 2003 | 350 | 0.050 |
Why?
| | Chromosome Aberrations | 2 | 2018 | 297 | 0.050 |
Why?
| | Uridine Triphosphate | 1 | 2003 | 10 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2014 | 1517 | 0.050 |
Why?
| | Catheter-Related Infections | 2 | 2014 | 49 | 0.050 |
Why?
| | Pertussis Toxin | 1 | 2002 | 9 | 0.050 |
Why?
| | Biopolymers | 1 | 2002 | 15 | 0.050 |
Why?
| | Virulence | 2 | 2014 | 163 | 0.050 |
Why?
| | Receptors, Scavenger | 1 | 2002 | 29 | 0.050 |
Why?
| | Macrophages, Peritoneal | 1 | 2002 | 30 | 0.050 |
Why?
| | Bacteremia | 2 | 2014 | 87 | 0.050 |
Why?
| | Scavenger Receptors, Class A | 1 | 2002 | 43 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2002 | 163 | 0.050 |
Why?
| | Atrial Natriuretic Factor | 1 | 2002 | 21 | 0.050 |
Why?
| | Actins | 1 | 2002 | 114 | 0.050 |
Why?
| | Adrenergic alpha-1 Receptor Agonists | 1 | 2002 | 4 | 0.050 |
Why?
| | Thymidine | 1 | 2002 | 16 | 0.050 |
Why?
| | Blotting, Northern | 1 | 2002 | 106 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 34 | 0.050 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2002 | 30 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2003 | 211 | 0.050 |
Why?
| | Primary Cell Culture | 1 | 2022 | 62 | 0.050 |
Why?
| | Genes, Reporter | 1 | 2002 | 87 | 0.050 |
Why?
| | Gene Knockdown Techniques | 1 | 2022 | 109 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2003 | 1544 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2002 | 128 | 0.040 |
Why?
| | Recombination, Genetic | 1 | 2022 | 95 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 92 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2002 | 267 | 0.040 |
Why?
| | Transfection | 1 | 2002 | 359 | 0.040 |
Why?
| | Cell Division | 1 | 2002 | 289 | 0.040 |
Why?
| | Imidazoles | 1 | 2002 | 114 | 0.040 |
Why?
| | B-Lymphocytes | 1 | 2022 | 178 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2002 | 149 | 0.040 |
Why?
| | Methionine | 1 | 2002 | 142 | 0.040 |
Why?
| | Phosphorylation | 1 | 2022 | 533 | 0.040 |
Why?
| | Cell Line | 1 | 2002 | 1016 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2002 | 315 | 0.040 |
Why?
| | Heart Ventricles | 1 | 2002 | 260 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1470 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2002 | 465 | 0.040 |
Why?
| | Fibroblasts | 1 | 2002 | 363 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 423 | 0.040 |
Why?
| | DNA | 1 | 2002 | 535 | 0.040 |
Why?
| | Pathology, Molecular | 1 | 2018 | 28 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 187 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2012 | 12 | 0.020 |
Why?
| | Daptomycin | 1 | 2012 | 29 | 0.020 |
Why?
| | Child | 1 | 2025 | 7379 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 2118 | 0.020 |
Why?
| | Cell Survival | 1 | 2013 | 600 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2012 | 274 | 0.020 |
Why?
| | Karyotyping | 1 | 2011 | 77 | 0.020 |
Why?
| | Biofilms | 1 | 2012 | 184 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 2991 | 0.020 |
Why?
| | Isotonic Solutions | 1 | 2010 | 19 | 0.020 |
Why?
| | Platelet Transfusion | 1 | 2010 | 33 | 0.020 |
Why?
| | P-Selectin | 1 | 2010 | 27 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2010 | 53 | 0.020 |
Why?
| | Receptors, LDL | 1 | 2010 | 73 | 0.020 |
Why?
| | Platelet Aggregation | 1 | 2010 | 77 | 0.020 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 13 | 0.020 |
Why?
| | Platelet Activation | 1 | 2010 | 48 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2012 | 271 | 0.020 |
Why?
| | Hypersensitivity | 1 | 2010 | 83 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 203 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2010 | 175 | 0.020 |
Why?
| | NF-kappa B | 1 | 2010 | 327 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2010 | 170 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 392 | 0.020 |
Why?
| | Short Bowel Syndrome | 1 | 2008 | 17 | 0.020 |
Why?
| | Parenteral Nutrition, Total | 1 | 2008 | 28 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2008 | 18 | 0.020 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 39 | 0.020 |
Why?
| | Niacinamide | 1 | 2008 | 24 | 0.020 |
Why?
| | Radiography, Thoracic | 1 | 2008 | 67 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2012 | 830 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 233 | 0.020 |
Why?
| | Mutation | 1 | 2011 | 1337 | 0.010 |
Why?
| | Brain Neoplasms | 1 | 2008 | 319 | 0.010 |
Why?
| | Adrenergic Agonists | 1 | 2003 | 6 | 0.010 |
Why?
| | Purinergic P1 Receptor Antagonists | 1 | 2003 | 2 | 0.010 |
Why?
| | Purinergic P2 Receptor Antagonists | 1 | 2003 | 3 | 0.010 |
Why?
| | Phospholipase C gamma | 1 | 2003 | 4 | 0.010 |
Why?
| | Phospholipase C beta | 1 | 2003 | 2 | 0.010 |
Why?
| | Type C Phospholipases | 1 | 2003 | 10 | 0.010 |
Why?
| | Phenylephrine | 1 | 2003 | 36 | 0.010 |
Why?
| | Perfusion | 1 | 2003 | 49 | 0.010 |
Why?
| | Vasoconstriction | 1 | 2003 | 55 | 0.010 |
Why?
| | Hypertrophy | 1 | 2003 | 53 | 0.010 |
Why?
| | Cyclic AMP | 1 | 2003 | 91 | 0.010 |
Why?
| | Aorta | 1 | 2003 | 172 | 0.010 |
Why?
| | Electrocardiography | 1 | 2003 | 273 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2008 | 1583 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2003 | 1367 | 0.010 |
Why?
|
|
Post's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|